Over the last decade, there has been an increasing interest in the management of obesity, with many newer medications being introduced and approved by various regulatory bodies. Better understanding and advancing knowledge of the gastrointestinal, endocrine, and neurological pathways involved in the pathophysiology of obesity has also opened newer avenues for the development of novel therapies in the management of obesity and associated co-morbidities.